Monkeypox primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 7: | Line 7: | ||
==Pre-exposure Prophylaxis== | ==Pre-exposure Prophylaxis== | ||
The Advisory Committee on Immunization Practices (ACIP) recommends ACAM2000 or JYNNEOS as pre-exposure prophylaxis to individuals whose work may expose them monkeypox. | The Advisory Committee on Immunization Practices (ACIP) recommends ACAM2000 or JYNNEOS as pre-exposure prophylaxis to individuals whose work may expose them monkeypox<ref name="pmid35653347">{{cite journal| author=Rao AK, Petersen BW, Whitehill F, Razeq JH, Isaacs SN, Merchlinsky MJ | display-authors=etal| title=Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. | journal=MMWR Morb Mortal Wkly Rep | year= 2022 | volume= 71 | issue= 22 | pages= 734-742 | pmid=35653347 | doi=10.15585/mmwr.mm7122e1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=35653347 }} </ref>. | ||
*ACAM2000 is an FDA approved active immunization against smallpox disease for persons determined to be at high risk for smallpox infection<ref name="urlACAM2000 | FDA">{{cite web |url=https://www.fda.gov/vaccines-blood-biologics/vaccines/acam2000 |title=ACAM2000 | FDA |format= |work= |accessdate=2022-06-16}}</ref>. | *ACAM2000 is an FDA approved active immunization against smallpox disease for persons determined to be at high risk for smallpox infection<ref name="urlACAM2000 | FDA">{{cite web |url=https://www.fda.gov/vaccines-blood-biologics/vaccines/acam2000 |title=ACAM2000 | FDA |format= |work= |accessdate=2022-06-16}}</ref>. | ||
| Line 13: | Line 13: | ||
*JYNNEOSTM, also known as Imvamune or Imvanex, is an FDA approved vaccine to prevent monkeypox and smallpox in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection<ref name="urlJYNNEOS | FDA">{{cite web |url=https://www.fda.gov/vaccines-blood-biologics/jynneos |title=JYNNEOS | FDA |format= |work= |accessdate=2022-06-16}}</ref>. | *JYNNEOSTM, also known as Imvamune or Imvanex, is an FDA approved vaccine to prevent monkeypox and smallpox in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection<ref name="urlJYNNEOS | FDA">{{cite web |url=https://www.fda.gov/vaccines-blood-biologics/jynneos |title=JYNNEOS | FDA |format= |work= |accessdate=2022-06-16}}</ref>. | ||
The US Centers for Disease Control and Prevention (CDC), in conjunction with ACIP, recommends vaccination with ACAM2000 in non-emergency settings to: | The US Centers for Disease Control and Prevention (CDC), in conjunction with ACIP, recommends vaccination with ACAM2000 in non-emergency settings to<ref name="urlMonkeypox and Smallpox Vaccine Guidance | Monkeypox | Poxvirus | CDC">{{cite web |url=https://www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox-vaccine.html |title=Monkeypox and Smallpox Vaccine Guidance | Monkeypox | Poxvirus | CDC |format= |work= |accessdate=2022-06-16}}</ref>: | ||
*Labradorians performing diagnostic testing for monkeypox and military personnel | *Labradorians performing diagnostic testing for monkeypox and military personnel | ||
*Persons investigating monkeypox outbreaks and involved in caring for infected individuals | *Persons investigating monkeypox outbreaks and involved in caring for infected individuals | ||
Revision as of 10:39, 16 June 2022
|
Monkeypox Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Monkeypox primary prevention On the Web |
|
American Roentgen Ray Society Images of Monkeypox primary prevention |
|
Risk calculators and risk factors for Monkeypox primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Bassel Almarie, MD
Overview
Pre-exposure Prophylaxis
The Advisory Committee on Immunization Practices (ACIP) recommends ACAM2000 or JYNNEOS as pre-exposure prophylaxis to individuals whose work may expose them monkeypox[1].
- ACAM2000 is an FDA approved active immunization against smallpox disease for persons determined to be at high risk for smallpox infection[2].
- JYNNEOSTM, also known as Imvamune or Imvanex, is an FDA approved vaccine to prevent monkeypox and smallpox in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection[3].
The US Centers for Disease Control and Prevention (CDC), in conjunction with ACIP, recommends vaccination with ACAM2000 in non-emergency settings to[4]:
- Labradorians performing diagnostic testing for monkeypox and military personnel
- Persons investigating monkeypox outbreaks and involved in caring for infected individuals
- Research laboratory personnel who directly handle cultures, contaminated animals or infected humans
CDC does not recommend pre-exposure vaccination for unexposed veterinarians, veterinary staff, or animal control officers, unless such persons are involved in field investigations.
References
- ↑ Rao AK, Petersen BW, Whitehill F, Razeq JH, Isaacs SN, Merchlinsky MJ; et al. (2022). "Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022". MMWR Morb Mortal Wkly Rep. 71 (22): 734–742. doi:10.15585/mmwr.mm7122e1. PMID 35653347 Check
|pmid=value (help). - ↑ "ACAM2000 | FDA". Retrieved 2022-06-16.
- ↑ "JYNNEOS | FDA". Retrieved 2022-06-16.
- ↑ "Monkeypox and Smallpox Vaccine Guidance | Monkeypox | Poxvirus | CDC". Retrieved 2022-06-16.